Weifa

Weifa is a Norwegian pharmaceutical company founded in 1940 by pharmacist Olaf Weider. The company is headquartered in Oslo and has production facilities in Kragerø. Its activities span finished pharmaceutical products, active pharmaceutical ingredients, and nutritional supplements, with a commercial emphasis on pain management, diabetes management, and consumer health. The company’s Norwegian portfolio has included several widely recognized over-the-counter and prescription-associated brands. Its pain-relief range includes Ibux, a brand of ibuprofen; Paracet, a paracetamol brand; Paracetduo, which combines paracetamol with caffeine; Proxan, based on naproxen; Fanalgin, a pain and fever product containing caffeine; and Paralgin Forte, a branded analgesic product mentioned in descriptions of the company’s Norwegian business. Weifa has also marketed Ibux Gel for topical use. Other consumer-health products have covered cough and cold symptoms, nasal care, vitamins, minerals, and topical preparations. Examples include Bronkyl, Tussin, Dexyl, Nazamér, Nazaren, Ferromax, Fluormax, Weifa-C Nypeekstrakt, Weifa C-vitamin brusetabletter, Weifa Kalsium, Pyrivir, Samin, and Tigerbalsam. In addition to branded medicines, Weifa has been associated with the manufacture of pharmaceutical ingredients. The company has been described as one of the world’s larger producers of metformin hydrochloride, an active ingredient used widely in first-line treatment of type 2 diabetes, and as a leading producer of alkaloid opiates. Its manufacturing facilities operate according to Good Manufacturing Practice standards, reflecting the quality and regulatory requirements applicable to pharmaceutical production. Weifa’s business model has combined domestic brand leadership with international sales and industrial pharmaceutical expertise. Its Norwegian pain-management portfolio has historically accounted for a substantial share of domestic sales, while branded products have represented approximately 70 percent of net sales according to the supplied reference material. Germany and the United Kingdom have been identified as leading export markets, with a broader presence across Europe and selected markets in Africa, the Americas, and Asia. The company’s stated development priorities have included international expansion, expertise in pharmaceuticals and fine chemicals, and partnership agreements. The supplied reference material describes a workforce of more than 99 employees and annual turnover of approximately €40 million, but it does not provide a dated reporting period or a source URL suitable for retaining those figures as verified current financial data. Corporate ownership, listing status, current operating status, and present-day management are therefore left unspecified in this dossier. Weifa’s historical identity is best understood as a Norwegian pharmaceutical and consumer-health company whose activities combined branded medicines with ingredient manufacturing.

Weifa was established in 1940 by Olaf Weider, a pharmacist. From its base in Norway, the company developed into a pharmaceutical manufacturer with headquarters in Oslo and production facilities in Kragerø. Its activities came to include both consumer-facing medicines and industrial production of pharmaceutical ingredients. A central part of Weifa’s development was the creation and marketing of branded products for the Norwegian healthcare and pharmacy markets. Pain management became the company’s most prominent therapeutic area, supported by brands such as Ibux, Paracet, Paracetduo, Proxan, Fanalgin, and Paralgin Forte. These products gave Weifa a significant position in Norwegian pain management, while additional products addressed coughs, colds, nasal symptoms, topical discomfort, vitamins, minerals, and food supplementation. Weifa also developed capabilities in pharmaceutical chemistry and active-ingredient production. It has been identified as a major producer of metformin hydrochloride and a leading producer of alkaloid opiates. Metformin is widely used in medicines for type 2 diabetes, while alkaloid opiates are used in analgesic and other pharmaceutical applications. This ingredient-manufacturing activity complemented the company’s branded-product business and gave it an industrial role beyond the Norwegian consumer market. The company’s manufacturing operations were described as complying with Good Manufacturing Practice standards. Its growth strategy was associated with three priorities: international expansion, technical expertise in pharmaceuticals and fine chemicals, and partnership agreements. Germany and the United Kingdom were cited as important export markets, alongside a wider presence in European, African, American, and Asian markets. The company’s branded products were reported to account for approximately 70 percent of net sales, indicating the importance of consumer and pharmacy brands within its overall business mix. The supplied reference material describes a company with more than 99 employees and annual turnover of approximately €40 million, including an international component. Because no reporting year or independently usable financial source URL is supplied for those figures, they are not treated here as current financial facts. The available material also does not establish Weifa’s present ownership, management, listing status, or whether all historical brands remain active. Accordingly, this dossier records Weifa primarily as a historically documented Norwegian pharmaceutical company and leaves unresolved corporate-status fields as unknown.

• 1940

  Company founded

  [1]Weifaen.wikipedia.org

  Pharmacist Olaf Weider founded Weifa in Norway.

A Norwegian pharmaceutical and consumer-health company combining established domestic medicine brands with pharmaceutical-ingredient manufacturing and international exports.

• Pain relief

  Ibux

  A Weifa brand based on ibuprofen and positioned for pain and inflammation relief. Ibux has been identified as one of the company’s established Norwegian pain-management brands.

• Pain relief and fever reduction

  Paracet

  A paracetamol brand used for relief of pain and fever. It has been described as one of Weifa’s leading branded products in Norway.

• Combination analgesic

  Paracetduo

  A product related to the Paracet range that adds caffeine to paracetamol for enhanced pain-relief positioning.

• Analgesic

  Paralgin Forte

  A branded analgesic product included among the established pain-management offerings associated with Weifa’s Norwegian portfolio.

• Pain relief

  Proxan

  A Weifa brand based on naproxen for pain-management use.

• Topical pain relief

  Ibux Gel

  A topical gel version of the Ibux pain-relief brand.

• Pharmaceutical active ingredient

  Metformin hydrochloride

  An active pharmaceutical ingredient used in medicines for type 2 diabetes. Weifa has been described as one of the world’s larger producers of metformin hydrochloride.

• Cough medicine

  Bronkyl

  An effervescent expectorant tablet intended to help relieve cough-related symptoms.

• Nasal care

  Nazamér and Nazaren

  Nasal-spray products associated with saline or salt-water nasal care.

• Vitamins and minerals

  Weifa nutritional supplements

  A group of supplement products including Ferromax iron supplements, Fluormax fluoride supplements, Weifa-C Nypeekstrakt vitamin C from rose-hip extract, Weifa C-vitamin effervescent tablets, and Weifa Kalsium calcium supplements.

1. 1Weifaen.wikipedia.org